Organization | Sysmex Inostics GmbH

Sysmex Inostics GmbH Report issue

For profit Phase 3

Founded: Tokyo Japan (1961)

Organization Overview

First Clinical Trial

2009

NCT00982111

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2010

Timeline

NOW

Now

Active Ingredients

Drugs in Phase 3 Trials (4)

cisplatin (platinol) (2 trials)

gemcitabine (gemzar) (1 trial)

necitumumab (portrazza) (2 trials)

pemetrexed (alimta) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Lung Neoplasms (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 2
# of Trial APIs: 4